Join Theravance Biopharma for a virtual key opinion leader (KOL) event featuring Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of patients with MSA. Dr. Kaufmann will also review ampreloxetine as a potential precision therapy approach in development for nOH in patients with MSA.

In anticipation of the Phase 3 CYPRESS study topline results in the first quarter of 2026, the event will also provide an overview of the ongoing CYPRESS study of ampreloxetine, and the strategic design choices of the study, informed by the positive results observed in patients with MSA in the REDWOOD study. Additionally, Company management will summarize ampreloxetine’s commercial opportunity and strategy.

A live question and answer session will follow the formal presentations.